Martin Koch
Direttore operativo presso Inotrem SA
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Jean-Jacques Garaud | M | 69 |
Inotrem SA
 Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 11 anni |
| Thierry Hercend | M | - |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
| Marc Derive | M | - |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 11 anni |
| Luke Beshar | M | 65 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
| Thomas Möller | M | 54 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
| François Thomas | M | 66 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
| Sven Zimmermann | M | 53 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 3 anni |
| Graziano Seghezzi | M | 55 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
| Gilles Nobécourt | M | 67 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
| Ena Prossner | M | 58 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 4 anni |
| Jason Robert Dinges | M | 48 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Kevin E. Moley | M | 77 |
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | - |
| Bryan Geoffrey Morton | M | 67 |
Zeneus Pharma Ltd.
 Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | 2 anni |
| Guillaume Floch | M | - |
Zeneus Pharma Ltd.
Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | 6 anni |
| John Dawson | M | 64 |
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | 11 anni |
| Eric Siegel | M | 60 |
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | 3 anni |
| Charles Swingland | M | - |
Zeneus Pharma Ltd.
Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | - |
| Diogo António Rodrigues da Silveira | M | 62 |
INSEAD
| 1 anni |
| Andrew Edward Anson | M | 59 |
INSEAD
| 2 anni |
| Antonio Miranda | M | - |
INSEAD
| - |
| Francois-Alfred-Mari Pinchon | M | 72 |
INSEAD
| 4 anni |
| Adolfo Carvajal Isla | M | - |
INSEAD
| - |
| Donald Charles McQueen | M | 62 |
INSEAD
| 2 anni |
| Jan Derck van Karnebeek | M | 57 |
INSEAD
| 2 anni |
| Neil C. McArthur | M | 63 |
INSEAD
| 2 anni |
| Bruno Duarte | M | 58 |
INSEAD
| 4 anni |
| Nicolas Martin | M | - |
INSEAD
| 2 anni |
| Didier Marginedès | M | 69 |
INSEAD
| 2 anni |
| Pedro de Boeck | M | 59 |
INSEAD
| 2 anni |
| Jarkko Tapio Sairanen | M | 61 |
INSEAD
| 2 anni |
| Francisco Ravara Cary | M | 58 |
INSEAD
| 2 anni |
| Jean-Luc Lowinski | M | 60 |
INSEAD
| 2 anni |
| Christel Elise Borge | F | 57 |
INSEAD
| 2 anni |
| Jorge Bento Ribeiro Barbosa Farinha | M | - |
INSEAD
| 2 anni |
| Alessandro Maria Decio | M | 58 |
INSEAD
| 1 anni |
| Roland Unfried | M | - |
INSEAD
| 2 anni |
| David Pitman | M | - |
INSEAD
| 1 anni |
| Renier Lemmens | M | 60 |
INSEAD
| 2 anni |
| Per-Olof Attinger | M | 64 |
INSEAD
| 2 anni |
| Troels Bugge Henriksen | M | 60 |
INSEAD
| 2 anni |
| Fabrice Desmarescaux | M | - |
INSEAD
| 1 anni |
| Yuji Ito | M | 60 |
INSEAD
| 2 anni |
| Kate Philips | F | - |
INSEAD
| 4 anni |
| Simon Griffiths | M | - |
INSEAD
| - |
| Vasileios Koutentakis | M | 61 |
INSEAD
| 2 anni |
| Enrica Acuto Jacobacci | F | - |
INSEAD
| 3 anni |
| Olivier Baldassari | M | - |
INSEAD
| 2 anni |
| Christina Law | F | 57 |
INSEAD
| 2 anni |
| Kevin Ryan | M | 60 |
INSEAD
| 1 anni |
| Enrico Berton | M | 58 |
INSEAD
| 1 anni |
| Jean-Marc Etlin | M | - |
INSEAD
| 1 anni |
| Jan Robin Waaler | M | 73 |
INSEAD
| 2 anni |
| Diogo Francisco Bastos Mendes Rezende | M | 57 |
INSEAD
| 1 anni |
| Anna Elisabet Nyquist | F | 62 |
INSEAD
| 2 anni |
| Thierry Noel | M | 54 |
Institut National Agronomique Paris-Grignon
| 4 anni |
| Minter Dial | M | 59 |
INSEAD
| 2 anni |
| Susanne Wamsler | F | 63 |
INSEAD
| 2 anni |
| Fernando Musa | M | 58 |
INSEAD
| 2 anni |
| Anders B. Christjansen | M | - |
INSEAD
| 2 anni |
| Roar Engeland | M | 64 |
INSEAD
| 2 anni |
| Roy Merritt | M | 60 |
INSEAD
| - |
| Bernhard Schmidt | M | 63 |
INSEAD
| 2 anni |
| C. Hultner | M | - |
INSEAD
| 1 anni |
| André S. Hoffmann | M | 66 |
INSEAD
| 2 anni |
| Fausto Boni | M | 59 |
INSEAD
| 2 anni |
| Mika Jerry Salmi | M | 58 |
INSEAD
| 2 anni |
| John Witt | M | 61 |
INSEAD
| 2 anni |
| Ranieri de Marchis | M | 63 |
INSEAD
| 2 anni |
| Michael Buhl | M | 65 |
INSEAD
| 2 anni |
| Simon Guild | M | 59 |
INSEAD
| 2 anni |
| James W. Schubauer | M | - |
INSEAD
| 2 anni |
| Eric I. Steiner | M | 57 |
INSEAD
| 2 anni |
| Niels Bjørn Christiansen | M | 58 |
INSEAD
| 2 anni |
| Bernardo Sanchez Incera | M | 64 |
INSEAD
| 2 anni |
| Jeremy Samuel John Marshall | M | 61 |
INSEAD
| 2 anni |
| Manuel Cubero del Castillo-Olivares | M | 61 |
INSEAD
| 2 anni |
| Paolo Vagnone | M | 60 |
INSEAD
| 2 anni |
| Helge Lund | M | 61 |
INSEAD
| 2 anni |
| Evan R. McCordick | M | - |
INSEAD
| - |
| Corrado Sciolla | M | 61 |
INSEAD
| 2 anni |
| Peter Paul Praxmarer | M | 66 |
INSEAD
| 2 anni |
| Horst Witzel | M | - |
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | - |
| Valerio Bellamoli | M | 64 |
INSEAD
| 2 anni |
| Mario Reis | M | 64 |
INSEAD
| 1 anni |
| Hubert-Lance Huet | M | - |
INSEAD
| 2 anni |
| Yvonne Greenstreet | M | 61 |
INSEAD
| 2 anni |
| Ludovic de Meeus d'Argenteuil | M | - |
INSEAD
| 2 anni |
| Anders Hove | M | 58 |
INSEAD
| 1 anni |
| Fionnuala Clare Duggan | F | 59 |
INSEAD
| 1 anni |
| Luke Jensen | M | 58 |
INSEAD
| 2 anni |
| Martin Vorderwülbecke | M | 63 |
INSEAD
| 2 anni |
| Georg Stratenwerth | M | 64 |
INSEAD
| 2 anni |
| Enrico Petocchi | M | - |
INSEAD
| 1 anni |
| Isidoro Miranda Fernández | M | 65 |
INSEAD
| 2 anni |
| Henrik Clausen | M | 61 |
INSEAD
| 2 anni |
| David John Cook | M | 57 |
Zeneus Pharma Ltd.
Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | 2 anni |
| Fritz Mumenthaler | M | 66 |
INSEAD
| 1 anni |
| Christian Hassel | M | 61 |
INSEAD
| 2 anni |
| Philippe Demigné | M | 63 |
INSEAD
| 2 anni |
| Marie-Gabrielle Ineichen-Fleisch | F | 63 |
INSEAD
| 2 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Francia | 92 | 92.00% |
| Regno Unito | 4 | 4.00% |
| Stati Uniti | 4 | 4.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Martin Koch
- Contatti personali
